Status:
COMPLETED
The Role of the EKG in Anticancer Drug Development
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Advanced Cancer
Eligibility:
All Genders
Brief Summary
Primary Objective: -Evaluate incidence of cardiac complications in Phase I patients. Secondary Objective: -To identify variables (i.e. number of electrocardiograms (EKG) performed) that lead to the...
Detailed Description
The research plan includes a retrospective review of the chart of past UT MD Anderson Cancer Center (MDACC) patients and the experience in treating them. All studies analyzed will be Phase I clinical...
Eligibility Criteria
Inclusion
- All types of advanced cancer
Exclusion
- N/A
Key Trial Info
Start Date :
January 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2011
Estimated Enrollment :
525 Patients enrolled
Trial Details
Trial ID
NCT01462383
Start Date
January 1 2011
End Date
November 1 2011
Last Update
December 12 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030